Therapies in development. Overview by Kevin McFarthing.

Kevin McFarthing: “I was diagnosed with Parkinson’s in 2012.  As a scientist, I tried to find out as much as I could about the condition.  Part of that was to investigate potential therapies that may be of benefit in the future.  This resulted in an ad ho list that needed organising in a spreadsheet.  Following lots of collecting, the spreadsheet below contains 200 identified projects, split into clinical and research/pre-clinical phases. I’ve probably missed some; I’ve undoubtedly made some mistakes.  Please let me know of any additions or corrections.  In the meantime I have only one conclusion – there really is a lot going on out there.”

  1. Summary
  2. Clinical research
  3. Research phases
  4. Inactive research

Please feel free to add, correct or comment via our contact page.


Therapies in development. Overview.

RESEARCH/PRE-CLINICAL CLINICAL 
Discovery47Phase 131
Pre-clinical57Phase 241
Research program6Phase 38
Proof of concept8
Submitted2
TOTAL110TOTAL90
Symptom relief22
Disease modifying87Symptom relief49
Not clear1Disease modifying41
TOTAL110TOTAL90
NCE93NCE48
Reformulation6Reformulation14
Repurpose7Repurpose21
Cells2Cells4
Gene therapy1Non-invasive surgery1
Protein extract1Gene therapy1
Botanical1
TOTAL110TOTAL90

Clinical phase

COMPANYTHERAPYWHAT IS IT?STATUSOBJECTIVETYPE
Acorda TherapeuticsCVT-301 (Inbrija)Inhaled L-DOPASubmittedSymptom reliefReformulation
Acorda TherapeuticsSYN-120Dual antagonist of 5-HT6 and 5-HT2APhase 2Symptom relief (cognitive)NCE
Addex TherapeuticsDipraglurantmGlur5 inhibitorPhase 2aSymptom relief (LID)NCE
AffirisPD01/PD03aSN vaccinePhase 1Disease modifierNCE
Amarantus BioscienceEltoprazine5-HT partial agonistPhase 2Symptom relief (LID)NCE
Amarantus BioscienceMANFMesencephalic astrocyte-derived neutotrophic factorPhase 1Disease modifierNCE
Anavex Life Sciences2-73Targets sigma receptorsPhase 1Disease modifierNCE
ApoPharma/Fair Park II/Cure Parkinson's TrustDeferiproneIron chelatorPhase 3Disease modifierRepurpose
Astra Zeneca (owns Bydureon)/UCL/CPTExenatide (Bydureon)Type 2 diabetes drugProof of conceptDisease modifierRepurpose
Astra Zeneca / TakedaMEDI1341aSN antibodyPhase 1Disease modifierNCE
Avanir PharmaceuticalsNuedextaDextromethorphan/quinidinePhase 1Symptom relief (LID)Repurpose
AxovantNelotanserin5H2A inverse agonistPhase 2Symptom relief DLB and PDDNCE
BioElectron (formerly Edison Pharna)BioE-743 and BioE-589Improves mitochondrial functionPhase 2aDisease modifierNCE
BiogenBIIB054aSN antibodyPhase 2Disease modifierNCE
CleraCLR4001Dopamine receptor modulatorPhase 2aSymptom reliefNCE
Clevexel/DomainCVXL-107Glutamate release inhibitorPhase 2aSymptom reliefNCE
Colorado University, DenverPhenylbutyrateThought to clear aSNPhase 1Disease modifierRepurpose
Contera PharmaJM-0105-HT1 receptor agonist combinationsPhase 2aSymptom relief (LID)NCE
Cure Parkinson's Trust/UCLAmbroxolGcase enhancerProof of conceptDisease modifierRepurpose
Cure Parkinson's TrustSimvastatinCholesterol lowering statinProof of conceptDisease modifierRepurpose
Cure Parkinson's Trust/University of QueenslandMCC 950Inflammasome inhibitorProof of conceptDisease modifierRepurpose
Dart NeuroscienceHT-3951MAO-B inhibitorPhase 2Symptom reliefNCE
Denali TherapeuticsDNL-201Lysosomal function enhancerPhase 1Disease modifierNCE
Denali TherapeuticsDNL-151Lysosomal function enhancerPhase 1Disease modifierNCE
DizlinInfudopaSub-cutaneous L-DOPAPhase 2?Symptom reliefReformulation
Dong-ADA9805Botanical extractPhase 2aDisease modifierBotanical
EnterinENT-01Displaces aSN aggregatesPhase 2aDisease modifierNCE
GenervonGM608Motoneuronotrophic factor (MNTF)Phase 2aDisease modifierNCE
HerantisCDNFCerebral dopamine neurotrophic factorPhase 1/2Disease modifierNCE
HisamItsuHP-3000Ropinirole patchPhase 3Symptom reliefReformulation
Hopitaux de ParisBuspirone5HT1A agonistPhase 3Symptom relief (LID)Repurpose
Impax PharmaIPX203L-DOPA/carbidopa extended releasePhase 2Symptom reliefReformulation
InSightec LtdExAblate NeuroMR guided focused ultrasoundPhase 1Symptom reliefNon-invasive surgery
Intec PharmaAccordion PillL-DOPA/carbidopa extended releasePhase 3Symptom reliefReformulation
Integrative research laboratoriesIRL 790"Psychomotor stabiliser"Phase 2Symptom relief (LID)NCE
Integrative research laboratoriesIRL 752"Cortical enhancer"Phase 2Symptom relief (PD dementia)NCE
International Stem Cell CorporationISC-hpNSCNeural stem cellsPhase 1Disease modifierStem cells
Intra-cellular TherapiesITI-214PDE-1 inhibitorPhase 1/2Symptom reliefNCE
Io TherapeuticsIRX4204RXR agonist (nuclear retinoid receptors)Phase 1Disease modifierNCE
Jazz PharmaceuticalsJZP-110Selective dopamine and norepinephrine reuptake inhibitorPhase 2Symptom relief (daytime sleepiness)NCE
Kainos MedicineKM819FAF-q inhibitorPhase 1Disease modifierNCE
KisseiKDT--3594DA receptor stimulationPhase 1Symptom reliefNCE
Kyowa HakkoIstradefylline (Nouriast)A2a receptor antagonistSubmitted? (marketed in Japan)Symptom relief (LID)NCE
Kyowa HakkoKW6356A2a receptor antagonistPhase 2Symptom reliefNCE
Ligand PharmaceuticalsAplindoreD2 agonistPhase 2Symptom reliefNCE
Living Cell TechnologiesNTCELLEncapsulated choroid plexus cellsPhase 2bDisease modifierCells
Luye PharmaLY03003Rotigotine extended releasePhase 1Symptom reliefReformulation
Lysosomal Therapeutics/AllerganLTI-291Gcase inhibitorPhase 1Disease modifierNCE
Medgenesis Therapeutix/ U of Bristol/PUK/CPT/MJFFBVF-014GDNFPhase 2Disease modifierNCE
Michael J Fox FoundationIsradipineCalcium channel blockerPhase 3Symptom reliefRepurpose
Michael J Fox Foundation/NIC-PDNicotine patchNicotinePhase 2Disease modifierRepurpose
Michael J Fox Foundation / U of RochesterBuspironeAnxiolytic 5HT1A agonistPhase 2Symptom relief (anti-anxiety)Repurpose
Michigan UniversityClarithromycinGABA-A modulatorProof of conceptSymptom reliefRepurpose
Minnesota UniversityUDCA (ursodeoxycholic acid)Improves mitochondrial functionPhase 1Disease modifierRepurpose
Mitsubishi Tanabe/NeurodermND0612Sub-cutaneous L-DOPAPhase 2Symptom reliefReformulation
Neurmedix (ex-Harbor Therapeutics)NE3107 (HE3286)Anti-inflammatoryPhase 1Symptom relief (LID)NCE
NeurogenerationStem cellsPhase 1Disease modifierStem cells
Neurohealing PharmaceuticalsNH004Tropicamide thin filmPhase 2Symptom relief (drooling)Reformulation
Neuropore + UCBNPT 200-11/UCB-1332Inhibitor of aSN aggregationPhase 1Disease modifierNCE
Novartis/MJFF/CPT/Van AndelNilotinibc-Abl inhibitorPhase 2Disease modifierRepurpose
Novo Nordisk/Cure Parkinson's Trust/Cedars-SinaiLiraglutideGLP-1 agonistProof of conceptDisease modifierRepurpose
Ono PharmaceuticalsONO-2160L-DOPA prodrug +carbidopaPhase 1Symptom reliefNCE
Oregon Health & Science UniversityBuspirone/amantadine5HT1A agonist + amantidinePhase 2Symptom relief (LID)Repurpose
OrionODM-104COMT inhibitorPhase 2Symptom reliefNCE
Oryzon GenomicsORY-2001LSD-1 MAOB inhibitorPhase 1Symptom reliefNCE
Oxford BiomedicaOXB-102Gene therapyPhase 1Disease modifierGene therapy
The Parkinson Study Group/MJFFInosineUrate precursorPhase 3Disease modifierRepurpose
PeptronPT 320 and 330SR Exenatide 2 weeksPhase 1Disease modifierRepurpose
Pharma Two BP2B001Rasagiline/pramiprexole combinationPhase 3Symptom reliefReformulation
PharnextPXT864Baclofen and acamprosate combinationPhase 1Symptom reliefRepurpose
Prexton Therapeutics/DomainFoligluraxmGlur4 inhibitorPhase 2Symptom reliefNCE
Prothena/RochePRX002/RO7046015Immunotherapy (Mab to aSN)Phase 2Disease modifierNCE
QR PharmaPosiphenaSN (+tau +APP) aggregation inhibitorPhase 2Disease modifierNCE
Raqualia PharmaRQ-00000010Serotonin 4 receptor partial agonistPhase 1Symptom relief (constipation)NCE
Saarland UniversityRESISTA-PDResistant starchPhase 2Symptom relief (constipation)Repurpose
SanofiLixisenatideGLP-1 agonistProof of conceptDisease modifierRepurpose
Sanofi/GenzymeGZ/SAR402671Inhibitor of aSN aggregation in patients with GCAse mutationsPhase 2Disease modifierNCE
Serina TherapeuticsSER-214Continuous delivery of L-DOPAPhase 1Symptom reliefReformulation
SK BiopharmaceuticalsYKP-10461Selective, reversible MAO-B inhibitorPhase 1Disease modifierNCE
SunovionSEP-363856Non-D2 psychotropicPhase 2Symptom relief (PD psychosis)NCE
SunovionDSP 6745Serotonin 2A and 2C receptor antagonistsPhase 1Symptom relief (PD psychosis)NCE
Sunovion (acquired Cynapsus)APL-130277Apomorphine thin film stripPhase 3Symptom reliefReformulation
Sunovion (acquired Cynapsus)SEP-3638565-HT1 receptor agonistPhase 2Symptom relief (PD psychosis)NCE
SynAgileOraFuseContinuous delivery of L-DOPA/CarbidopaPhase 2aSymptom reliefReformulation
TauRxLMTXTau aggregation inhibitorPhase 1Disease modifierNCE
Teikoku PharmaTPU-0027-day rasagiline patchPhase 1Symptom reliefReformulation
Titan PharmaceuticalsRopinirole implant3 month depotPhase 1/2Symptom reliefReformulation
TranseuroFetal stem cellsProof of conceptDisease modifierCells
VernalisV81444Adenosine receptor antagonistPhase 1Symptom reliefNCE
Voyager TherapeuticsVY-AADC01AV-hAADC gene therapyPhase 2Disease modifierGene therapy

Research phases.

COMPANYTHERAPYWHAT IS IT?STATUSOBJECTIVETYPE
4P TherapeuticsTransdermal apomorphinePre-clinicalSymptom reliefReformulation
AC ImmuneMorphomer aSNSmall molecule to inhibit aSN aggregationPre-clinicalDisease modifierNCE
AC ImmuneAntibodies to aSN and TDP-43DiscoveryDisease modifierNCE
AcelotJPS platformLRRK2 inhibitorsDiscoveryDisease modifierNCE
Addex TherapeuticsmGluR4 PAMDiscoveryDisease modifierNCE
Addex TherapeuticsTyrosine receptor kinase PAMsDiscoveryDisease modifierNCE
Aeolus PharmaceuticalsAEOL 11114Reduces oxidative stressPre-clinicalDisease modifierNCE
AffirisPD04aSN vaccinePre-clinicalDisease modifierNCE
AlkahestGRF6019Plasma protein extractPre-clinicalDisease modifierProtein extract
AmabioticsAMA-101Microbiome modifier? Not clear.Pre-clinicalDisease modifierNCE
American Gene TechnologiesAG-PDTherapeutic lentivirusDiscoveryDisease modifierNCE
Anavex Life Sciences3-71Targets sigma receptorsPre-clinicalDisease modifierNCE
Anavex Life Sciences1-41Targets sigma receptorsPre-clinicalDisease modifierNCE
AngitaAG-0029D2 agonist/H3 antagonistDiscoverySymptom reliefNCE
AntoxisProxisonInhibits oxidative stressDiscoveryDisease modifierNCE
APeT Holding BVConstadopaTwice daily dosingDiscoverySymptom reliefNCE
AposenseATT-LDL-DOPA prodrugPre-clinicalSymptom reliefNCE
Aracion BiotechS14PDE-7 inhibitorPre-clinicalDisease modifierNCE
ArmagenResearch programDiscoveryDisease modifierNCE
Arrien PharmaceuticalsARN-1104LRRK2 inhibitorPre-clinicalDisease modifierNCE
Axial BiotherapeuticsMicrobiome and PDResearch programDisease modifierNCE
Berg HealthInterrogative biologyDiscoveryDisease modifierNCE
Bioarctic (partnered with Eisai and Abbvie)BAN0805aSN antibodyPre-clinicalDisease modifierNCE
Blue Rock therapeutics (+ Bayer)iPSC researchiPSCResearch programDisease modifierStem cells
Carmot Therapeutics/AmgenDiscovery programmeDiscoveryDisease modifierNCE
Cantabio PharmaceuticalsCB101Targets DJ-1Pre-clinicalDisease modifierNCE
Cantabio PharmaceuticalsCB201Cell penetrant DJ-1 proteinPre-clinicalDisease modifierNCE
Carna BiosciencesTargets kinasesDiscoveryDisease modifierNCE
CerevancePre-clinicalDisease modifierNCE
ChipscreenChiglitazarPPAR Pan inhibitorPre-clinicalDisease modifierNCE
Clevexel/DomainCVXL-0069Dual adenosine receptor inhibitorPre-clinicalSymptom relief (MS and NMS)NCE
CuremarkCM-PK?Pre-clinicalSymptom relief (LID)NCE
Denali TherapeuticsATV:aSynAntibodyPre-clinicalDisease modifierNCE
DermaxonDX0308Retinoic acid metabolism inhibitorPre-clinicalDisease modifierNCE
Domain therapeuticsDT011088mGluR3 allosteric modulatorPre-clinicalSymptom reliefNCE
Domain therapeuticsmGluR2 blockerDiscoverySymptom reliefNCE
Eli LillyDETQD1 potentiatorPre-clinicalSymptom reliefNCE
Emerald Health PharmaceuticalsEHP-102Antinflammatory cannabinoidPre-clinicalDisease modifierNCE
Ensemble therapeuticsCyclophilin antagonistsPre-clinicalDisease modifierNCE
Fabre-Kramer PharmaceuticalsFKK01PDApomorphine prodrugsPre-clinicalSymptom reliefNCE
Gene SolutionsmtDNA focused discovery programDiscoveryDisease modifierNCE
GenecodeGDNF family ligand (GFL) mimeticsDiscoveryDisease modifierNCE
GenentechDiscoveryDiscoveryDisease modifierNCE
GenkyotexNADPH oxidase inhibitorsDiscoveryDisease modifierNCE
GenoscoLRRK2 inhibitorsDiscoveryDisease modifierNCE
ICB InternationalSMART molecules targetting aSNDiscoveryDisease modifierNCE
ImmungeneticsABC transporter protein enhancersPre-clinicalDisease modifierNCE
Impel NeuroPharmaINP-103Inhaled L-DOPAPre-clinicalSymptom reliefReformulation
Integrative research laboratoriesIRL448/IRL555?DiscoverySymptom relief (LID)NCE
Jeil PharmaceuticalStem cell discovery programmeDiscoveryDisease modifierNCE
JunaxoJNX3001Trehalose as autophagy enhanceerPre-clinicalDisease modifierRepurpose
Keapstone TherapeuticsDiscovery programmeDiscoveryDisease modifierNCE
KhondrionKH176Prevents mitochondrial dysfunctionPre-clinicalDisease modifierNCE
Lead Discovery CenterLRRK2 programmeDiscoveryDisease modifierNCE
Longevity BiotechLBT-3627VIP receptor agonistPre-clinicalDisease modifierNCE
LundbeckPFE-360LRRK2 inhibitorPre-clinicalDisease modifierNCE
M's Science CorporationMC116Sigma 1 receptor agonistPre-clinicalDisease modifierNCE
M et P PharmaNasal delivery of dopaminePre-clinicalSymptom reliefReformulation
Mavalon Therapeutics/DomainmGluR3 PAMDiscoveryDisease modifierNCE
Merck/Parkinson's InstituteLRRK2 inhibitorsPre-clinicalDisease modifierNCE
Metabolic Solutions DevelopmentMSDC-0160mTOT modulatorPre-clinicalDisease modifierNCE
Michael J Fox Foundation/Binghamton U/Wayne State UD-512D2/D3 receptor agonistPre-clinicalDisease modifierNCE
Minerva NeurosciencesMIN-301Neuregulin 1b1 peptidePre-clinicalDisease modifierNCE
Mission TherapeuticsUSP30 targetsPre-clinicalDisease modifierNCE
Mitochon PharmaceuticalsMP-201Mitochondrial modulatorDiscoveryDisease modifierNCE
Mitodys TherapeuticsDiscoveryDisease modifierNCE
Mitsubishi Tanabe/NeurodermND0701Sub-cutaneous apomorphinePre-clinicalSymptom reliefReformulation
Modag/Cure Parkinson's TrustAnle 138bInhibits aSN oligomerisationPre-clinicalDisease modifierNCE
MotacD3 receptor agonists / u opiod receptor antagonists 5-HT1a agonistsDiscoverySymptom reliefNCE
Netherlands Translational Research CentreTrytophan oxygenase targetDiscoveryDisease modifierNCE
NeuraltusNP001 (IV sodium chlorite)Regulates activated macrophagesPre-clinicalDisease modifierNCE
NeurodynND1208NeuroprotectantDiscoveryDisease modifierNCE
NeurodynProgranulin ND 602NeuroprotectantDiscoveryDisease modifierNCE
NeurlixisNLX-1125HT-1A inhibitorPre-clinicalSymptom relief (LID)NCE
NeuronascentNNI-362 and NNI370 (backup)NeurorestorativeDiscoveryDisease modifierNCE
NeuropGlu N2C/DNMDA receptor blockerDiscoverySymptom reliefNCE
New World LaboratoriesNWL-283Cell regeneration peptidesDiscoveryDisease modifierNCE
New World LaboratoriesPersonalised neural stem-like cellsDiscoveryDisease modifierNCE
nLife TherapeuticsNLF-PD 1233Antisense oligo/drug conjugatesDiscoveryDisease modifierNCE
NLS PharmaQuinoleinePre-clinicalSymptom reliefRepurpose
NLS PharmaTryptaminePre-clinicalSymptom reliefRepurpose
NLS PharmaAminoquinoxalinePre-clinicalSymptom reliefRepurpose
OPKO HealthSR-3306jun-terminal kinase inhibitorsDiscoveryDisease modifierNCE
OxStemEndogenous cell activation therapyResearch programDisease modifierNCE
ParkurePre-clinicalDisease modifierRepurpose
PeptronPT 304SR Exenatide 1 monthPre-clinicalDisease modifierRepurpose
PharmatrophixP75 small molecule receptor programPrevents neurodegenerationDiscoveryDisease modifierNCE
Plex Pharmaceuticals (formerly Calasia)Targets misfolded proteinsDiscoveryDisease modifierNCE
Prana Biotechnology/TakedaPBT 434Metal Protein Attenuating CompoundsPre-clinicalDisease modifierNCE
Prevail TherapeuticsNAV AAV9 vectorResearch programDisease modifierGene therapy
Primary PeptidesPP-003Small peptide decreasing aSNPre-clinicalDisease modifierNCE
Proclara (formerly Neurophage)GAIMTargets misfolded proteinsPre-clinicalDisease modifierNCE
Promius PharmaResearch programPre-clinical??
Proteostasis Therapeutics (+Biogen)USP14 inhibitorsDiscoveryDisease modifierNCE
ReMYNDReS9-S and ReS12-SModifying aSN toxicityPre-clinicalDisease modifierNCE
RetrotopePrevent cell damage from oxidative stressDiscoveryDisease modifierNCE
Rodin TherapeuticsEpigenetic regulationResearch programDisease modifierNCE
SanBioSB623Cell therapyPre-clinicalDisease modifierCells
SanionaNicotinic a6 receptor modulatorsPre-clinicalDisease modifierNCE
Sheffield UniversityUrsodeoxycholic acidImprove mitochondrial dysfunctionPre-clinicalDisease modifierRepurpose
Synpromics/UCLSynthetic gene promotersResearch programDisease modifierNCE
SynthonicsMetal coordinated pharmaceuticalsExtend absorption phase of L-DOPADiscoverySymptom reliefReformulation
TauRxG2 PDDiscoveryDisease modifierNCE
TechnophageTZ-113Pre-clinicalDisease modifierNCE
UCLACLR01Binds to lysine residues to prevent aSN aggregationPre-clinicalDisease modifierNCE
Vanton Research LabsODT-SROrally dissolving L-DOPA and carbidopaPre-clinicalSymptom reliefReformulation
VistaGen TherapeuticsAV-101 (L-4-chlorokyurenine or 4-CI-KYN)NMDAR GlyB modulatorDiscoveryDisease modifierNCE
VivaCell BiotechnologyVCE-003.2Cannabinoid derivativesDiscoveryDisease modifierNCE
Wellstat TherapeuticsWT501Oral agent for mitochondrial diseaseDiscoveryDisease modifierNCE
Yumanity TherapeuticsProtein misfoldingResearch programDisease modifierNCE

Research - inactive.

Therapies on market, stopped or no up to date data available   
COMPANYTHERAPYWHAT IS IT?STATUSOBJECTIVETYPE
Acorda Therapeutics (Biotie)Tozadenant SYN-115A2a inhibitorPhase 3Symptom reliefNCE
CellceutixKM362Stops demyelinationDiscoveryDisease modifierNCE
Euroscreen/OgedaESN502?Discovery?NCE
FPRT BioXPro1595TNF modifier to prevent neuroinflammationPre-clinical (inactive?)Disease modifierNCE
Intermed DiscoveryIMD-026259HIF-1 inhibitorDiscoveryDisease modifierNCE
Xenoport/Arbor PharmaXP21279L-DOPA pro drugSuspendedSymptom reliefNCE
Adamas PharmaADS-5102Extended-release amantadineApprovedSymptom relief (LID)Reformulation
Impax PharmaIPX-066/RytaryL-DOPA/carbidopa extended releaseApprovedSymptom reliefReformulation
Osmotica PharmaceuticalOsmolex-ERExtended release amantidineFDA approvedSymptom relief (LID)Reformulation
Astra Zeneca AZD3241Myeloperoxidase inhibitorDiscontinuedDisease modifierNCE
CeregeneCERE-120 AAV-NTN gene therapyDiscontinuedDisease modifierNCE
Michael J Fox Foundation GlutathioneAntioxidantPhase 2Disease modifierRepurpose
Neuronova (now Newron)PDGF-BBGrowth factorPhase 1/2Disease modifierNCE
Prana BiotechnologyClioquinolLysosome enhancerProof of conceptDisease modifierRepurpose
PfizerPF-06649751 Dopamine signalling modulatorPhase 2Symptom reliefNCE
SellasZolpidemSelective GABA-A-BZ1 receptorsPhase 2Symptom reliefRepurpose
TevaSD-1077DeulevodopaPhase 1Symptom reliefReformulation
Uniqure/UCSF/NIHAMT-140Gene therapy with AAV2-GDNFPhase 1Disease modifierGene therapy
HeptaresmGluR5 inhibitorsDiscoveryDisease modifierNCE
NeuralstemNSI-566Cell therapyPre-clinicalDisease modifierCells
NSGene/TakedaNsG0301Cell repair platform delivering GDNFPre-clinicalDisease modifierNCE
Park CellAutologous cell transplantationPre-clinicalDisease modifierCells
PfizerResearch programDiscoveryDisease modifierNCE
PromentisGlutamergic discovery programDiscoveryDisease modifierNCE
Reset TherapeuticsOrexin receptor modulatorsDiscoverySymptom relief (sleep)NCE
RhinocyteNasal derived stem cellsDiscoveryDisease modifierStem cells
STATegicsCytokine receptor modulatorsDiscoveryDisease modifierNCE
University of New MexicoFlubendazolePromotes autophagyPre-clinicalDisease modifierRepurpose

 

Team P.R.A.G.

We are an international group of 8 people, connected by Parkinson’s Disease, aiming to influence the Parkinson’s Disease research agenda through research advocacy. We have been working together as a team for nearly a year. Each of us brings significant experience, activism and stamina to the advocacy table. Our group, as well as our readers on social media, is bound together by the urgent need of over 6 million people of a future without the ever increasing burden of Parkinson’s Disease.

Leave a Reply